Increased blood levels of platelet‐activating factor in insulin‐dependent diabetic patients with microalbuminuria

Cavallo‐Perin, P.; Lupia, Enrico; Gruden, Gabriella; Olivetti, C; Martino, Antonella De; Cassader, Maurizio; Furlani, Daniela; Servillo, Luigi; Quagliuolo, Lucio; Iorio, Eugenio Luigi; Boccellino, Marcia Rosario; Montrucchio, G; Camussi, Giovanni

doi:10.1093/ndt/15.7.994

Cited by 31 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In regard to patients with DM 1, Cavallo-Perin et al 28 did not find any difference in PAF-AH activity among groups of patients with DM 1 without microalbuminuria, with microalbuminuria, and control subjects. Although they did not find any difference in PAF-AH activity among the groups…”

Section: Discussionmentioning

confidence: 89%

“…3). The stepwise multiple regression using PAF-AH activity as a dependent variable and age, gender, BMI, HbA1c, HDL and LDL as independent variables showed HDL and LDL as independent explanatory variables of changes in PAF-AH activity (step 1: r = 0.231, r2 studied, Cavallo-Perin et al 28 and Nathan et al 27 demonstrated that PAF levels are increased in patients with DM 1, and that this would be basically associated with a higher production of this particle. The disagreement between data found by these authors and our own may reflect the characteristics of the population studied -our sample had a lower age range, no microvascular complications and lower BMI, as well as the sample size -42 diabetics versus 7 patients with microalbuminuria and 7 without microalbuminuria assessed by Cavallo-Perin et al The higher PAF-AH activity in patients with DM 1 may represent an attempt at protection against pathophysiological mechanisms induced by increased levels of PAF found in these patients 34 or may exert pro-inflammatory and pro-atherogenic effects 30,32,33 .…”

Section: Resultsmentioning

confidence: 95%

“…There is controversy in the literature regarding the importance of the PAF-AH activity and concentration in the atherosclerotic process [27][28][29][30][31][32][33] . Some studies demonstrate that patients with DM 1 have low levels of PAF-AH, unlike patients with DM 2 27,29 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

Castro¹,

Neto²,

Gomes³

2007

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

SummaryObjective: To evaluate platelet-activating factor acetylhydrolase (PAF-AH) activity and its relationship with clinical and demographic variables, metabolic control, apolipoprotein A and B levels and the susceptibility of low-density lipoprotein (LDL) to in vitro oxidation in patients with type 1 diabetes mellitus (DM 1).Methods: Forty two patients with DM 1 (27 females) and 48 control subjects (16 females) matched for gender, age and body mass index (BMI) were evaluated. The following tests were performed: fast plasma glucose (FG) and postprandial plasma glucose (PPG), lipid profile, uric acid (UA), glycosylated hemoglobin (HbA1c), and low-density lipoprotein (LDL) oxidation rate using colorimetric assay. The PAF-AH activity was analyzed using colorimetric assay (Cayman Chemical).Results: The analysis of PAF-AH activity showed a higher enzyme activity in patients with DM 1 than in control subjects (0.0150 + 0.0051 vs. 0.0116 + 0.0041; p < 0.001). In patients with DM 1, a direct correlation between PAF-AH activity and age and LDL, and an inverse correlation between PAF-AH and HbA1c and high-density lipoprotein (HDL) were found.Conclusion: In the sample studied, PAF-AH showed a higher activity in patients with DM 1, a factor that may be related to the higher risk of developing cardiovascular diseases observed in these patients. Further studies are necessary to evaluate the real participation of this enzyme in the risk of development of atherosclerotic diseases in patients with DM 1.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

Castro¹,

Neto²,

Gomes³

2007

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…Plateletactivating factor (PAF) is an ether lipid of choline, and its presence has been demonstrated in a variety of eye tissues, including the retina, ciliary body, and iris (1,8,27). PAF and its metabolite lyso-PAF are potent inflammatory lipids, and PAF and lyso-PAF levels are elevated in serum of type 1 diabetic patients (4,10), as well as in oxygen-induced retinopathy (2). Intravenous injection of PAF into rabbits induced an intense ischemia accompanied by a marked plasma leakage (26).…”

mentioning

confidence: 99%

A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice

Cheng

Han

Shi

2009

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…Some studies demonstrate that patients with DM have decreased activity of PAF-AH [9,36]. Cavallo-Perin et al [37] did not find any difference in PAF-AH activity between groups of patients with DM1 and control subjects. In our study, we did oxidative stress.…”

Section: Discussionmentioning

confidence: 93%

Increased Asymmetric Dimethylarginine (ADMA) levels and Decreased Homocysteine Thiolactonase/Paraoxonase (HTLase/PONase) activities are Related to the Risk of Cardiovascular Disease in Prediabetic/Diabetic Patients.

Bayrak¹,

Bayrak²,

Işildak³

et al. 2014

Turk J Bioch

View full text Add to dashboard Cite

Increased asymmetric dimethylarginine (ADMA) levels and decreased homocysteine thiolactonase/paraoxonase (HTLase/PONase) activities are related to the risk of cardiovascular disease in prediabetic/diabetic patients [Prediyabetik/diyabetik hastalarda artmış asimetrik dimetilarjinin (ADMA) ve azalmış homosistein tiyolaktonaz/paraoksonaz (HTLase/PONase) aktiviteleri kardiyovasküler hastalık riski ile ilişkilidir] ABSTRACTObjective: Individuals with impaired glucose tolerance and/or impaired fasting glucose are at high risk, not only to develop diabetes mellitus, but also to experience cardiovascular disease later in their life. The aim of this study was to evaluate the cardiovascular risk markers (such as serum ADMA, homocysteine, high-sensitivity C-reactive protein, small dense LDL levels, paraoxonase/homocysteine thiolactonase and platelet-activating factor acetylhydrolase activities between patients with diabetes, prediabetes, and control group. Methods: Subjects were grouped as Type 2 diabetes mellitus (n=20), IGT (n=16), IFG (n=19) and control group (n=23). Enzyme activities were measured spectrophotometrically. ADMA levels were measured by HPLC. Serum concentrations of homocysteine were measured by fluorescence polarization immunoassay. sLDL was measured by using heparin-magnesium precipitation method. h-CRP was measured by using immuno nephelometric method. Results: Plasma ADMA levels were significantly lower in the control group than the IFG, IGT, DM groups (p<0.05, p<0.01, p<0.01 respectively). Serum HTLase activity was significantly higher in the control group than in the IFG, IGT, DM groups (p<0.01, p<0.01, p<0.001 respectively). No difference was found in plasma Hcy, sLDL, h-CRP concentrations and PAF-AH acivity between groups. Conclusion: We concluded that increased ADMA levels and decreased HTLase/PONase activities in prediabetic patients can indicate that the risk of atherosclerosis in prediabetic stage.

show abstract

Increased blood levels of platelet‐activating factor in insulin‐dependent diabetic patients with microalbuminuria

Abstract: These results indicate an association between increased production of PAF and enhanced glomerular permeability in microalbuminuric IDD patients.

Cited by 31 publications

References 19 publications

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice

Increased Asymmetric Dimethylarginine (ADMA) levels and Decreased Homocysteine Thiolactonase/Paraoxonase (HTLase/PONase) activities are Related to the Risk of Cardiovascular Disease in Prediabetic/Diabetic Patients.

Contact Info

Product

Resources

About